A Medicxi-backed startup looks to tackle treatment-resistant blood cancers, and it’s going after AML first

In the hardest-to-treat blood cancers, resistance to therapy is an existential problem for drug developers looking to permanently stave off tumors. A small biotech is chasing an emerging pathway to stop tumors’ ability to resist treatment, and its work has caught the eye of a couple of big-name investors.

Kurome...

Click to view original post